Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc.
100 Campus Drive
Florham Park, NJ 07932
United States
608 441 8120
https://www.cellectar.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 20
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. James V. Caruso | President, CEO & Director | 1.14M | N/D | 1959 |
| Mr. Chad J. Kolean CPA | VP, CFO & Secretary | 711.23k | N/D | 1964 |
| Mr. Jarrod Longcor | Chief Operating Officer | 854.24k | N/D | 1973 |
| Mr. Darrell Shane Lea | Chief Commercial Officer | N/D | N/D | 1974 |
| Dr. Andrei Shustov M.D. | Senior Vice President of Medical | N/D | N/D | 1972 |
Descripción
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de Cellectar Biosciences, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
